Yi, J.W.; Hong, H.P.; Kim, M.S.; Shin, B.S.; Kwon, H.-J.; Kim, B.I.; Sohn, W.
Comparison of Clinical Efficacy and Safety between 70–150 µm and 100–300 µm Doxorubicin Drug-Eluting Bead Transarterial Chemoembolization for Hepatocellular Carcinoma. Life 2022, 12, 297.
https://doi.org/10.3390/life12020297
AMA Style
Yi JW, Hong HP, Kim MS, Shin BS, Kwon H-J, Kim BI, Sohn W.
Comparison of Clinical Efficacy and Safety between 70–150 µm and 100–300 µm Doxorubicin Drug-Eluting Bead Transarterial Chemoembolization for Hepatocellular Carcinoma. Life. 2022; 12(2):297.
https://doi.org/10.3390/life12020297
Chicago/Turabian Style
Yi, Jung Woo, Hyun Pyo Hong, Myung Sub Kim, Byung Seok Shin, Heon-Ju Kwon, Byung Ik Kim, and Won Sohn.
2022. "Comparison of Clinical Efficacy and Safety between 70–150 µm and 100–300 µm Doxorubicin Drug-Eluting Bead Transarterial Chemoembolization for Hepatocellular Carcinoma" Life 12, no. 2: 297.
https://doi.org/10.3390/life12020297
APA Style
Yi, J. W., Hong, H. P., Kim, M. S., Shin, B. S., Kwon, H.-J., Kim, B. I., & Sohn, W.
(2022). Comparison of Clinical Efficacy and Safety between 70–150 µm and 100–300 µm Doxorubicin Drug-Eluting Bead Transarterial Chemoembolization for Hepatocellular Carcinoma. Life, 12(2), 297.
https://doi.org/10.3390/life12020297
